Experience

Papillon Therapeutics Inc

• CEO

  • Feb 2023 - 11 months

  San Diego, California, United States Multi-systemic hematopoietic stem and progenitor cell (HSPC)-based gene therapies for life-threatening inherited conditions including Cystinosis, Friedreich's ataxia, and Danon disease. HIGHLIGHT: Papillon's lead program targeting Cystinosis reported positive Ph1/2 data and is now licensed to Novartis.



StemCardia

• France
• Technology, Information and Internet
• 1 - 100 Employee

• President

  • May 2023 - 8 months

  Pluripotent Stem Cell (PSC)-based cardiomyocyte and other heart cell replacement as disease-modifying regenerative medicines for treatment of Heart Failure. HIGHLIGHT: StemCardia was spun out of University of Washington with a broad portfolio of programs previously developed in partnership with Sana Biotechnology.



Vascugen

• United States
• Biotechnology
• 1 - 100 Employee

• Co-Founder | Director

  • Jun 2017 - 6 years 7 months

  Induced Pluripotent Stem Cell (iPSC)-based cell replacement therapy as disease-modifying regenerative medicine for vascular diseases including Critical Limb Threatening Ischemia (CLTI/CLI). HIGHLIGHT: Vascugen built out a fully dedicated manufacturing facility to conduct lead optimization and manufacture GMP clinical batches of working cell bank and product.



RPRD Diagnostics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder | Director

  • Oct 2016 - 7 years 3 months

  Actionable pharmacogenetics (PGx) testing for all ethnicities, marketing commercial testing across the US including the Psych HealthPGx Panel and Comprehensive CYP2C19 Test. HIGHLIGHT: RPRDx operates a fully dedicated CLIA-certified clinical diagnostic facility that performs the company's unique comprehensive pharmacogenomic (PGx) testing.



Saisei Ventures

• United States
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Venture Partner

  • Jun 2021 - 2 years 7 months

  VC fund that combines Western expertise and Japanese innovation to build globally competitive companies that will have the greatest impact on patient lives. HIGHLIGHT: Sasei is one of only nine VC funds certified by the Japan Agency for Medical Research and Development (AMED), who provide matching investment from the Japanese government.



D1ASP0RA

• United States
• Biotechnology Research

• Founder | Principal

  • Apr 2016 - 7 years 9 months

  Foundry for biotech ventures.



Ryne Biotechnology

• United States
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder | Director

  • Feb 2022 - Nov 2023

  Induced Pluripotent Stem Cell (iPSC)-based cell replacement therapy as disease-modifying regenerative medicine for neurological diseases including Parkinson's Disease. HIGHLIGHT: Ryne is partnered with leading iPSC company FUJIFILM Cellular Dynamics (FCDI) for clinical-grade manufacturing of its lead program (RNDP-001) targeting Parkinson's disease.



Dianomi Therapeutics

• United States
• Biotechnology Research

• Co-Founder | Director

  • Mar 2017 - 2020

  More stable protein & RNA drugs.



Opsis Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder

  • Jul 2016 - Nov 2019

  Induced Pluripotent Stem Cell (iPSC)-based cell replacement therapy as disease-modifying regenerative medicine for eye diseases including Retinitis Pigmentosa and Age-Related Macular Degeneration (AMD). HIGHLIGHT: Opsis entered into a Strategic R&D Alliance with BlueRock Therapeutics (a Bayer AG company) with $70 million up-front commitment.



Cellular Dynamics International

• Director Business Development

  • Jun 2010 - Mar 2016

  Madison, Wisconsin Area


Meso Scale Discovery
• Biotechnology Research
• Sales

  • Nov 2005 - Jun 2010

Invitrogen
• Biotechnology Research
• 1 - 100 Employee
• Field Applications

  • 2003 - 2005

Ingenuity Systems
• Biotechnology Research
• Scientific Consultant

  • 2001 - 2004

Upstate
• Biotechnology Research
• 1 - 100 Employee
• Sales

  • 2001 - 2003